A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield
Open accessThe DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.
Abstract
An HIV antibody achieves potency and breadth by binding simultaneously to two conserved glycans on the viral envelope protein.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Sometimes, such protective glycosylation can become so dense that it generates unique clustered epitopes recognized by speci fi c antibodies, such as that seen on the surface of the HIV virion (507 -509, 594).”
From Biological roles of glycans (2017) · cites this paper as [508]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
PHENIX : building new software for automated crystallographic structure determination
Adams, P. D., Grosse-Kunstleve, R. W., Hung, L.-W., Ioerger, T. R., McCoy, A. J., Moriarty, N. W., Read, R. J., Sacchettini, J. C., Sauter, N. K., & Terwilliger, T. C. (2002) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444902016657 · Cited by 4,361
EMAN2: An extensible image processing suite for electron microscopy
Tang, G., Peng, L., Baldwin, P. R., Mann, D. S., Jiang, W., Rees, I., & Ludtke, S. J. (2007) · Journal of Structural Biology · doi:10.1016/j.jsb.2006.05.009 · Cited by 2,994
Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J., & Hendrickson, W. A. (1998) · Nature · doi:10.1038/31405 · Cited by 2,964
EMAN: Semiautomated Software for High-Resolution Single-Particle Reconstructions
Ludtke, S. J., Baldwin, P. R., & Chiu, W. (1999) · Journal of Structural Biology · doi:10.1006/jsbi.1999.4174 · Cited by 2,391
Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
Wu, X., Yang, Z.-Y., Li, Y., Hogerkorp, C.-M., Schief, W. R., Seaman, M. S., Zhou, T., Schmidt, S. D., Wu, L., Xu, L., et al. (2010) · Science · doi:10.1126/science.1187659 · Cited by 1,730
Self-citationBroad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target
Walker, L. M., Phogat, S. K., Chan-Hui, P.-Y., Wagner, D., Phung, P., Goss, J. L., Wrin, T., Simek, M. D., Fling, S., Mitcham, J. L., et al. (2009) · Science · doi:10.1126/science.1178746 · Cited by 1,723
Self-citation
Cited by
Items 301–400 of 709
Struwe, W. B., Stuckmann, A., Behrens, A., Pagel, K., & Crispin, M. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00854 · Cited by 35
Self-citationCrooks, E. T., Osawa, K., Tong, T., Grimley, S. L., Dai, Y. D., Whalen, R. G., Kulp, D. W., Menis, S., Schief, W. R., & Binley, J. Μ. (2017) · Virology · doi:10.1016/j.virol.2017.02.024 · Cited by 34
Self-citationGlycosylation as a key parameter in the design of nucleic acid vaccines
Ozdilek, A., & Avci, F. Y. (2022) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2022.102348 · Cited by 33
Goh, B. C., Rynkiewicz, M. J., Cafarella, T. M., White, M. R., Hartshorn, K. L., Allen, K., Crouch, E. C., Calin, O., Seeberger, P. H., Schulten, K. J., et al. (2013) · Biochemistry · doi:10.1021/bi4010683 · Cited by 33
Controlling the HIV/AIDS epidemic: current status and global challenges
Demberg, T., & Robert-Guroff, M. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00250 · Cited by 38
“…receptor (Arthos et al., 2008), role in viral transmission, binding to highly potent neutralizing antibodies (Doores and Burton, 2010; Collins-Fairclough et al., 2011; Pejchal et al., 2011) and recent correlation with reduced risk of HIV infection in the RV144 trial (Zolla-Pazner et al., 2011a).”
BackgroundOrwenyo, J., Cai, H., Giddens, J. P., Amin, M. A., Toonstra, C., & Wang, L. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00319 · Cited by 31
Kumar, S., Ju, B., Shapero, B., Lin, X., Ren, L., Zhang, L., Li, D., Zhou, Z., Feng, Y., Sou, C., et al. (2020) · Science Advances · doi:10.1126/sciadv.abb1328 · Cited by 31
Self-citationGoo, L., Jalalian‐Lechak, Z., Richardson, B. A., & Overbaugh, J. M. (2012) · Journal of Virology · doi:10.1128/jvi.01414-12 · Cited by 36
“For example, variants isolated from a number of patients, including Q769, QG984, QH209, and QH359, which were resistant to PGT121 and PGT128, lacked the N332 residue required for neutralization (22, 27).”
BackgroundStructure and Glycan Binding of a New Cyanovirin-N Homolog
Matei, E., Basu, R., Furey, W. F., Shi, J., Calnan, C., Aiken, C., & Gronenborn, A. M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.740415 · Cited by 31
“The crystal structure of the gp120 trimer clearly delineates the Asn(332) (Man8/9GlcNAc2) glycan as a key element in PGT122 recognition (39, 44).”
BackgroundSmith, S. A., Burton, S. L., Kilembe, W., Lakhi, S., Karita, E., Price, M. A., Allen, S. A., Hunter, E., & Derdeyn, C. A. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005989 · Cited by 34
Goo, L., Milligan, C., Simonich, C. A. L., Nduati, R. W., & Overbaugh, J. M. (2012) · Journal of Virology · doi:10.1128/jvi.00953-12 · Cited by 31
“In fact, for Msens1, we saw a markedly enhanced neutralization by maternal plasma when the N332A mutation was introduced ( 48% AUC reduction [Fig.”
BackgroundMethodInfluentialBanach, B. B., Pletnev, S. V., Olia, A. S., Xu, K. Y., Zhang, B., Rawi, R., Bylund, T., Doria‐Rose, N. A., Nguyen, T. D., Fahad, A. S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42098-5 · Cited by 30
Sampath, S., Carrico, C., Janes, J. H., Gurumoorthy, S., Gibson, C., Melcher, M., Chitnis, C. E., Wang, R., Schief, W. R., & Smith, J. D. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003420 · Cited by 33
Self-citationFlemming, J., Wiesen, L., & Herschhorn, A. (2018) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2018.0102 · Cited by 30
A Glycotherapeutic Approach to Functionalize Biomaterials‐Based Systems
Gadekar, A., Bhowmick, S., & Pandit, A. S. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201910031 · Cited by 31
HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design
Bricault, C. A., Yusim, K., Seaman, M. S., Yoon, H., Theiler, J. P., Giorgi, E. E., Wagh, K., Theiler, M., Hraber, P., Macke, J. P., et al. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.07.016 · Cited by 34
Stanfield, R. L., Castro, C. D., Marzaioli, A. M., Wilson, I. A., & Pantophlet, R. A. (2014) · Glycobiology · doi:10.1093/glycob/cwu123 · Cited by 31
Self-citationDesigning synthetic vaccines for HIV
Fernández‐Tejada, A., Haynes, B. F., & Danishefsky, S. J. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1027690 · Cited by 30
“The recently disclosed crystal structure of PGT128 Fab in complex with a Man9 oligosaccharide and a glycosylated, third variable (V3) loop domain of gp120 revealed that the epitope recognized by PGT128 consists of two conserved high-mannose glycans (at Asn(332) and Asn(301)) and a short b-strand C-terminal peptide fra…”
BackgroundAcharya, P., Luongo, T. S., Georgiev, I. S., Matz, J., Schmidt, S. D., Louder, M. K., Kessler, P., Yang, Y., McKee, K., O'Dell, S. J., et al. (2013) · Journal of Virology · doi:10.1128/jvi.01332-13 · Cited by 30
Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies
Ahmed, Y., Tian, M., & Gao, Y. (2017) · AIDS Research and Therapy · doi:10.1186/s12981-017-0178-3 · Cited by 30
Han, Q., Bradley, T., Williams, W. B., Cain, D. W., Montefiori, D. C., Saunders, K. O., Parks, R., Edwards, R. W., Ferrari, G., Mueller, O., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2019.12.091 · Cited by 31
“V3-glycan types of bnAbs make contact with the highly conserved GDIR motif (Gly324, Asp325, Ile326, and Arg327) at the base of the V3 loop (Garces et al., 2014; Pejchal et al., 2011; Sok et al., 2014) and KIF-JRFL neutralization was abrogated or decreased in all neonate and adult macaque plasmas by the G324A mutation…”
Anti-V1/V3-glycan broadly HIV-1 neutralizing antibodies in a post-treatment controller
Molinos-Albert, L. M., Baquero, E., Bouvin-Pley, M., Lorin, V., Charre, C., Planchais, C., Dimitrov, J. D., Monceaux, V., Vos, M. R. J., Hocqueloux, L., et al. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.06.006 · Cited by 29
Glycoform and Net Charge Heterogeneity in gp120 Immunogens Used in HIV Vaccine Trials
Yu, B., Morales, J. F., O’Rourke, S. M., Tatsuno, G. P., & Berman, P. W. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043903 · Cited by 29
“Recently, several potent bN MAbs (PGT 127 and 128) have been described [44] that preferentially recognize mannose-8 and mannose-9 structures in positions N301 and N332 for antibody binding [45].”
BackgroundHIV vaccine design: the neutralizing antibody conundrum
Stamatatos, L. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.04.006 · Cited by 32
Travers, S. A. A. (2012) · ISRN AIDS · doi:10.5402/2012/823605 · Cited by 33
“Walker and colleagues suggest that positions 332 and/or 301 are important for neutralisation by at least six of the BCN antibodies described in their study [30] and this observation was supported by a structural study by Pejchal and colleagues [31].”
BackgroundZhang, Y., Zheng, S., Zhao, W., Mao, Y., Cao, W., Zeng, W., Liu, Y., Hu, L., Gong, M., Cheng, J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.755568 · Cited by 29
“For example, 2G12, PGT121, PGT128, and PGT135 recognize the mannosedependent epitope on gp120 (14, 15).”
BackgroundSelf-citationAbnormal antibodies to self-carbohydrates in SARS-CoV-2-infected patients
Butler, D. L., Imberti, L., Quaresima, V., Fiorini, C., Barnett, J., Chauvin, S. D., Cheng, X., Danielson, J. J., Dobbs, K., Garabedian, E., et al. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac062 · Cited by 30
Benjelloun, F., Lawrence, P., Verrier, B., Genin, C., & Paul, S. (2012) · Journal of Virology · doi:10.1128/jvi.01110-12 · Cited by 29
“By addition of a leucine at each side (LELDKWASL), the affinity of 2F5 for its epitope is increased more than 2,000 times (82, 95, 100, 134).”
BackgroundInfluentialFera, D., Lee, M. S., Wiehe, K. J., Meyerhoff, R. R., Piai, A., Bonsignori, M., Aussedat, B., Walkowicz, W. E., Ton, T., Zhou, J. O., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03565-6 · Cited by 30
Toonstra, C., Wu, L. Y., Li, C., Wang, D., & Wang, L. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00145 · Cited by 30
Bowers, P. M., Verdino, P., Wang, Z., Correia, J. D. S., Chhoa, M., Macondray, G., Do, M., Neben, T. Y., Horlick, R. A., Stanfield, R. L., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.607176 · Cited by 28
Self-citationYen, P.-J., Herschhorn, A., Haim, H., Salas, I., Gu, C., Sodroski, J., & Gabuzda, D. H. (2014) · Journal of Virology · doi:10.1128/jvi.02785-13 · Cited by 28
Chen, Y., Vaine, M., Wallace, A., Han, D. G., Wan, S., Seaman, M. S., Montefiori, D. C., Wang, S., & Lu, S. (2013) · Journal of Virology · doi:10.1128/jvi.00837-13 · Cited by 28
“The other hybridomas, R20 and R43, recognized the C-terminal portion of the V3 region, an epitope not commonly seen by human MAbs but recently described as part of a key neutralizing epitope for several highly potent human MAbs, such as PGT128 (26).”
BackgroundSelf-citationReichart, T. M., Baksh, M. M., Rhee, J., Fiedler, J. D., Sligar, S. G., Finn, M. G., Zwick, M. B., & Dawson, P. E. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201508421 · Cited by 28
Jia, M., Lü, H., Markowitz, M. H., Cheng‐Mayer, C., & Wu, X. (2016) · Journal of Virology · doi:10.1128/jvi.02898-15 · Cited by 28
Liang, Y., Guttman, M., Williams, J. A., Verkerke, H., Alvarado, D., Hu, S.-L., & Lee, K. K. (2016) · Journal of Virology · doi:10.1128/jvi.01116-16 · Cited by 31
“actually targets for potent HIV-1 bNAbs (13-18).”
Morris, C. D., Azadnia, P., de Val, N., Vora, N., Honda, A., Giang, E., Saye-Francisco, K. L., Cheng, Y., Lin, X., Mann, C. J., et al. (2017) · mBio · doi:10.1128/mbio.00036-17 · Cited by 28
“Following computational design, His-tagged epitope scaffolds were transiently expressed in HEK-293 F cells with kifunensine to produce a Man8/9 glycan at the N332 position (23).”
BackgroundMethodInfluentialSelf-citationAntigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design
Kong, L., & Sattentau, Q. J. (2012) · Journal of AIDS & Clinical Research · doi:10.4172/2155-6113.s8-003 · Cited by 28
Gach, J. S., Achenbach, C. J., Chromikova, V., Berzins, B., Lambert, N., Landucci, G., Forthal, D. N., Katlama, C., Jung, B. H., & Murphy, R. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085371 · Cited by 27
“Nevertheless, two of these patients (#12 and #42) were able to neutralize HIV-1JR-FL in a single round infectivity assay suggesting either the occurrence of potent CD4bsspecific and V1/V2/V3-specific antibodies or the existence of neutralizing antibodies to other epitopes such as glycans [70,71].”
BackgroundThe Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses
Ringel, O., Vieillard, V., Debré, P., Eichler, J., Büning, H., & Dietrich, U. (2018) · Viruses · doi:10.3390/v10040197 · Cited by 33
“Camelids and cows both produce antibodies with longer HCDR3 (heavy-chain complementary determining regions), which is often a feature of bnAbs against HIV-1 [60].”
BackgroundBlasi, M., Negri, D., LaBranche, C., Alam, S. M., Baker, E. J., Brunner, E. C., Gladden, M. A., Michelini, Z., Vandergrift, N. A., Wiehe, K. J., et al. (2018) · Communications Biology · doi:10.1038/s42003-018-0131-6 · Cited by 27
Kluková, Ľ., Bertók, T., Petríková, M., Šedivá, A., Mislovičová, D., Katrlík, J., Vikartovská, A., Filip, J., Kasák, P., Andicsová, A. E., et al. (2014) · Analytica Chimica Acta · doi:10.1016/j.aca.2014.10.029 · Cited by 27
Immunogen design for HIV-1 and influenza
Rathore, U., Kesavardhana, S., Mallajosyula, V. V. A., & Varadarajan, R. (2014) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2014.05.010 · Cited by 29
Current Peptide and Protein Candidates Challenging HIV Therapy beyond the Vaccine Era
Chupradit, K., Moonmuang, S., Nangola, S., Kitidee, K., Yasamut, U., Mougel, M., & Tayapiwatana, C. (2017) · Viruses · doi:10.3390/v9100281 · Cited by 29
“Furthermore, there are multiple obstacles for inducing bNAbs as antiviral agents; for example, the designed immunogens display imprecise epitopes leading to inefficient bNAbs production and the glycosylation of the HIV envelope heavily covers the conserved sites of the envelope that are the binding sites of most bNAbs…”
BackgroundExploiting glycan topography for computational design of Env glycoprotein antigenicity
Yu, W., Zhao, P., Draghi, M., Arevalo, C. P., Karsten, C. B., Suscovich, T. J., Gunn, B. M., Streeck, H., Brass, A. L., Tiemeyer, M., et al. (2018) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006093 · Cited by 27
“However, while certain glycans may help shape individual epitopes [30, 31, 33, 34, 36, 51], glycans interact with one another, dynamically reshaping the exposed protein surface, coordinately influencing Ab binding access [37, 52–56].”
BackgroundSun, L., Paschall, A. V., Middleton, D. R., Ishihara, M., Ozdilek, A., Wantuch, P. L., Aceil, J., Duke, J. A., LaBranche, C. C., Tiemeyer, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16319-0 · Cited by 27
Lusvarghi, S., Lohith, K., Morin‐Leisk, J., Ghirlando, R., Hinshaw, J. E., & Bewley, C. A. (2016) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.6b00139 · Cited by 26
Palanichamy, K., Bravo, M. F., Shlain, M. A., Schiro, F., Naeem, Y., Marianski, M., & Braunschweig, A. B. (2018) · Chemistry - A European Journal · doi:10.1002/chem.201803317 · Cited by 26
Waltari, E., Jia, M., Jiang, C. S., Lü, H., Huang, J., Fernández, C., Finzi, A., Kaufmann, D., Markowitz, M. H., Tsuji, M., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00628 · Cited by 27
“These results are concordant with the importance of long heavy chain CDR3 in some HIV-1 bnAbs, allowing for reaching to deep and partially obscured regions of the HIV-1 envelope trimer (61, 62).”
ResultKuwata, T., Takaki, K., Yoshimura, K., Enomoto, I., Wu, F., Ourmanov, I., Hirsch, V. M., Yokoyama, M., Sato, H., & Matsushita, S. (2013) · Journal of Virology · doi:10.1128/jvi.00201-13 · Cited by 25
“The PGT128 epitope consists of the short segment of the V3 loop and 2 neighboring glycans (19), but the binding of B404 is independent of these glycans near the V3 region.”
BackgroundInfluentialZhang, M.-Y., Yuan, T., Li, J., Borges, A. R., Watkins, J. D., Guenaga, J., Yang, Z., Wang, Y., Wilson, R., Li, Y., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044241 · Cited by 25
“Co-crystallization of some of the bnmAbs with gp120 core protein or Env-derived peptides has revealed several conserved neutralizing epitopes [6,15,16,17,18,19,20,21].”
Evolution of B cell analysis and Env trimer redesign
Hedestam, G. B. K., Guenaga, J., Corcoran, M., & Wyatt, R. T. (2017) · Immunological Reviews · doi:10.1111/imr.12515 · Cited by 26
Directed Evolution of Glycopeptides Using mRNA Display
Horiya, S., Bailey, J. K., & Krauss, I. J. (2017) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2017.06.029 · Cited by 25
“…large family known as the “PGT” antibodies (Walker et al., 2011) bind to epitopes comprising three or four glycans and usually some polypeptide motifs on the HIV envelope protein gp120 (Calarese et al., 2003; Garces et al., 2014; Julien et al., 2013; Pejchal et al., 2011; Scanlan et al., 2002).”
BackgroundGift, S. K., Leaman, D. P., Zhang, L., Kim, A. S., & Zwick, M. B. (2017) · Journal of Virology · doi:10.1128/jvi.01216-17 · Cited by 25
“V3 extends outward from the crown to a conserved and exposed glycan at N332, which is a target of highly potent bnAbs including PGT121-122, PGT126, and PGT128 (15, 33, 34).”
BackgroundWu, X., & Kong, X. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.05.013 · Cited by 24
Behrens, A., Kumar, A., Medina-Ramírez, M., Cupo, A., Marshall, K., Portillo, V. M. C., Harvey, D. J., Ozorowski, G., Zitzmann, N., Wilson, I. A., et al. (2018) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00639 · Cited by 24
Self-citationde Taeye, S. W., Go, E. P., Sliepen, K., de la Peña, A. T., Badal, K., Medina-Ramírez, M., Lee, W.-H., Desaire, H., Wilson, I. A., Moore, J. P., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005396 · Cited by 24
Self-citationCharacterizing Carbohydrate–Protein Interactions by Nuclear Magnetic Resonance Spectroscopy
Bewley, C. A., & Shahzad‐ul‐Hussan, S. (2013) · Biopolymers · doi:10.1002/bip.22329 · Cited by 24
Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens
Sattentau, Q. J. (2013) · Vaccines · doi:10.3390/vaccines1040497 · Cited by 27
“However, recent crystallographic studies have revealed that glycans can also entirely comprise [33], or be a significant part [34–36], of neutralizing antibody epitopes, and so may in fact turn out to be part of the solution to the problem.”
BackgroundHumoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants
Lin, N., Gonzalez, O. A., Registre, L., Becerril, C., Etemad, B., Lü, H., Wu, X., Lockman, S., Essex, M., Moyo, S. M., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.04.040 · Cited by 24
Broadly Neutralizing Antibodies against HIV-1 As a Novel Aspect of the Immune Response
Щербаков, Д. Н., Bakulina, A., Карпенко, Л. И., & Ilyichev, A. A. (2015) · Acta Naturae · doi:10.32607/20758251-2015-7-4-11-21 · Cited by 28
Genetic and structural analyses of affinity maturation in the humoral response to HIV ‐1
Kepler, T. B., & Wiehe, K. J. (2017) · Immunological Reviews · doi:10.1111/imr.12513 · Cited by 25
Structural Features of Broadly Neutralizing Antibodies and Rational Design of Vaccine
Zhou, T., & Xu, K. Y. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-0484-2_4 · Cited by 24
Ravenscroft, N., Costantino, P., Talaga, P., Rodríguez–Jiménez, R., & Egan, W. (2014) · Springer eBooks · doi:10.1007/978-3-662-45024-6_8 · Cited by 27
Uukuniemi Phlebovirus Assembly and Secretion Leave a Functional Imprint on the Virion Glycome
Crispin, M., Harvey, D. J., Bitto, D., Halldórsson, S., Bonomelli, C., Edgeworth, M. J., Scrivens, J. H., Huiskonen, J. T., & Bowden, T. A. (2014) · Journal of Virology · doi:10.1128/jvi.01662-14 · Cited by 23
Self-citationWilliams, K. L., Wang, B., Arenz, D., Williams, J. A., Dingens, A. S., Cortez, V. A., Simonich, C. A. L., Rainwater, S. M. J., Lehman, D. A., Lee, K. K., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.082 · Cited by 23
“However, neither the heavy nor the light chain contained insertions or deletions (indels) commonly associated with N332-dependent nAbs (Bonsignori et al., 2017; Doores et al., 2015; MacLeod et al., 2016; Pejchal et al., 2011; Walker et al., 2011).”
BackgroundGlycans in HIV-1 vaccine design – engaging the shield
Deimel, L. P., Xue, X., & Sattentau, Q. J. (2022) · Trends in Microbiology · doi:10.1016/j.tim.2022.02.004 · Cited by 23
Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model
Zhen, A., Rezek, V. K., Youn, C., Rick, J. W., Lam, B. B., Chang, N. Y., Zack, J. A., Kamata, M., & Kitchen, S. G. (2016) · Journal of Visualized Experiments · doi:10.3791/54048-v · Cited by 23
Cai, H., Zhang, R., Orwenyo, J., Giddens, J. P., Yang, Q., LaBranche, C. C., Montefiori, D. C., & Wang, L. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01290 · Cited by 25
Engineering immunogens that select for specific mutations in HIV broadly neutralizing antibodies
Henderson, R. C., Anasti, K. M., Manne, K., Stalls, V., Saunders, C., Bililign, Y., Williams, A., Bubphamala, P., Montani, M., Kachhap, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53120-9 · Cited by 24
“Of note, D325 was identi fi ed as a signi fi cant neutralization sensitivity signature, and the mutationsN325orK325aresigni fi cantresistancesignaturesforDH270 lineage bnAbs, 10-1074, PGT121, and PGT128 29 , consistent with D325 mutations conferring in vivo escape to PGT121 30 or 10-1074 31 .”
Pham, T. N. Q., Lukhele, S., Dallaire, F., Perron, G., & Cohen, É. A. (2016) · Scientific Reports · doi:10.1038/srep37225 · Cited by 23
SELMA: Selection with Modified Aptamers
Temme, J. S., & Krauss, I. J. (2015) · Current Protocols in Chemical Biology · doi:10.1002/9780470559277.ch140233 · Cited by 22
“…for polymerase incorporation of the alkyne-containing 5-ethylnyl-dUTP (EdU) and subsequent glycosylation of the unnatural dsDNA by an azide sugar using click chemistry (Rostovtsev et al., 2002), SELMA was designed to employ click chemistry to attach Man9 azide sugars to an EdU-modified library.”
MethodFerguson, A. L., Falkowska, E., Walker, L. M., Seaman, M. S., Burton, D. R., & Chakraborty, A. K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080562 · Cited by 22
“While the neutralization activity for the isolate JRCSF was not sensitive to alanine mutation at position 332 [51], our predictions are supported by the crystal structure of PGT-128 bound to an engineered glycosylated gp120 outer domain (containing a JR-FL mini-V3 loop) which revealed the importance of positions 332 a…”
BackgroundResultInfluentialSelf-citationAntigenicity-defined conformations of an extremely neutralization-resistant HIV-1 envelope spike
Cai, Y., Karaca-Griffin, S., Chen, J., Tian, S., Fredette, N., Linton, C. E., Rits‐Volloch, S., Lü, J., Wagh, K., Theiler, J. P., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700634114 · Cited by 27
Determinants of Tenascin-C and HIV-1 envelope binding and neutralization
Mangan, R. J., Stamper, L., Ohashi, T., Eudailey, J., Go, E. P., Jaeger, F. H., Itell, H. L., Watts, B. E., Fouda, G. G., Erickson, H., et al. (2019) · Mucosal Immunology · doi:10.1038/s41385-019-0164-2 · Cited by 22
Structure-function relationship of the mammarenavirus envelope glycoprotein
Wang, W., Zhou, Z., Zhang, L., Wang, S., & Xiao, G. (2016) · Virologica Sinica · doi:10.1007/s12250-016-3815-4 · Cited by 22
Self-citationAlgal and Cyanobacterial Lectins and Their Antimicrobial Properties
Fernández Romero, J. A., Paglini, M. G., Priano, C., Koroch, A., Rodríguez, Y., Sailer, J., & Teleshova, N. (2021) · Marine Drugs · doi:10.3390/md19120687 · Cited by 21
Feizi, T. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12210 · Cited by 21
Self-citationMorales, J. F., Morin, T. J., Yu, B., Tatsuno, G. P., O’Rourke, S. M., Theolis, R., Mesa, K. A., & Berman, P. W. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.554089 · Cited by 21
Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies
Zhang, Z., Li, S., Gu, Y., & Xia, N. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111901 · Cited by 22
Advancements in Cell-Based Therapies for HIV Cure
Matsui, Y., & Miura, Y. (2023) · Cells · doi:10.3390/cells13010064 · Cited by 22
“For example, Hale et al. integrated single-chain variable fragments (scFv) from four distinct antibodies (VRC07-523 [48], PGT-128 [49], PGT-145 [50], and 10E8 [51]) as antigen-recognition domains within a CAR construct.”
BackgroundPotential targets for therapeutic intervention and structure based vaccine design against Zika virus
Qadir, A., Riaz, M. N., SAEED, M. K., & Shahzad‐ul‐Hussan, S. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.07.014 · Cited by 21
Multi-scale structural analysis of proteins by deep semantic segmentation
Eguchi, R. R., & Huang, P.-S. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btz650 · Cited by 18
Self-citationChang, C., Hinkula, J., Loo, M., Falkeborn, T., Li, R., Cardillo, T. M., Rossi, E. A., Goldenberg, D. M., & Wahrén, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041235 · Cited by 21
“On the other hand, newer antibodies with broader and more potent HIV-binding and neutralization activities across clades are continuously being identified or engineered [26], as exemplified by the more recently reported VRC01 [27], NIH-45-46 [28], and PGT128 [29].”
BackgroundFine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site
Cheng, H. D., Grimm, S. K., Gilman, M. S. A., Gwom, L. C., Sok, D., Sundling, C., Donofrio, G. C., Hedestam, G. B. K., Bonsignori, M., Haynes, B. F., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.97018 · Cited by 21
“Similarly, diverse vaccine design strategies have focused on the CD4bs, involving approaches that have matured from obscuring other surface residues (48), to minimizing the presence of other epitopes (49), to grafting the CD4bs onto alternative scaffolds (50), to designing modified CD4bs epitopes favoring interactions…”
BackgroundSelf-citationThe Evolution of Dendritic Cell Immunotherapy against HIV‐1 Infection: Improvements and Outlook
Mohamed, H., Miller, V., Jennings, S. R., Wigdahl, B. L., & Krebs, F. C. (2020) · Journal of Immunology Research · doi:10.1155/2020/9470102 · Cited by 20
“A previous strategy for circumventing anticipated challenges in obtaining the desired immunogenicity was the use of the in fl uenza A matrix protein as an adjuvant [19, 97].”
Cho, B. G., Reyes, C. D. G., Goli, M., Gautam, S., Banazadeh, A., & Mechref, Y. S. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c01975 · Cited by 20
Vaccines based on structure-based design provide protection against infectious diseases
Thomas, S., & Luxon, B. A. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2013.840092 · Cited by 20
Mabuka, J. M., Goo, L., Omenda, M. M., Nduati, R. W., & Overbaugh, J. M. (2013) · AIDS · doi:10.1097/qad.0b013e32835faba5 · Cited by 20
“Two other bNAbs, PGT121 and PGT128, target an epitope in the V3 loop, which includes conserved N-linked glycans at positions 301 and 332 [17,18].”
BackgroundAntiviral Vaccines: Challenges and Advances
Ellebedy, A. H., & Ahmed, R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802174-3.00015-1 · Cited by 23
“[98] [99] [100] [101] Sequence analysis of these antibodies and structural examination of their interactions with HIV antigens at the atomic level have strengthened our understanding of how these broadly neutralizing antibodies work.”
BackgroundShahzad‐ul‐Hussan, S., Sastry, M., Lemmin, T., Soto, C. S., Loesgen, S., Scott, D. A., Davison, J. R., Lohith, K., O'Connor, R., Kwong, P. D., et al. (2017) · ChemBioChem · doi:10.1002/cbic.201600665 · Cited by 20
Chemically Programmed Antibodies As HIV-1 Attachment Inhibitors
Sato, S., Inokuma, T., Otsubo, N., Burton, D. R., & Barbas, C. F. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400097z · Cited by 20
Self-citationGach, J. S., Quendler, H., Tong, T., Narayan, K. M., Du, S. X., Whalen, R. G., Binley, J. Μ., Forthal, D. N., Poignard, P., & Zwick, M. B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072054 · Cited by 21
“antibody (nAb) titers typically correlate with the protection conferred by many antiviral vaccines on the market today [3],”
BackgroundSelf-citationGlycosylation and Serological Reactivity of an Expression-enhanced SARS-CoV-2 Viral Spike Mimetic
Chawla, H., Jossi, S. E., Faustini, S. E., Samsudin, F., Allen, J. D., Watanabe, Y., Newby, M. L., Marcial‐Juárez, E., Lamerton, R. E., McLellan, J. S., et al. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167332 · Cited by 21
Self-citationStructural dynamics reveal isolate-specific differences at neutralization epitopes on HIV Env
Hodge, E. A., Naika, G. S., Kephart, S. M., Nguyen, A., Zhu, R., Benhaim, M. A., Guo, W., Moore, J. P., Hu, S., Sanders, R. W., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104449 · Cited by 19
“…al., 2017a); the CD4 binding site targeted by VRC01 class bnAbs (Wu et al., 2011); the V3 loop targeted by PGT121 class bnAbs (Mouquet et al., 2012; Pejchal et al., 2011); and the gp120/gp41 interface that includes the fusion peptide and is the target of bnAbs such as 35O22, PGT151, and VRC34…”
BackgroundSelf-citationLupo, C., Spisak, N., Walczak, A. M., & Mora, T. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010167 · Cited by 22
“Several works have shown a beneficial impact of indels for binding affinity and neutralization activity in vitro and in vivo [32, 40, 41], opening new evolutionary pathways beyond point mutations.”
BackgroundZhang, H., Fu, H., Luallen, R. J., Liu, B.-F., Lee, F.-H., Doms, R. W., & Geng, Y. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.08.012 · Cited by 19
“This is consistent with our viral glycan profile study in which the kifunensine-treated virus harbored only Endo H-sensitive high mannose type N-glycans (Fig.”
BackgroundInfluentialCai, H., Orwenyo, J., Guenaga, J., Giddens, J. P., Toonstra, C., Wyatt, R. T., & Wang, L. (2017) · Chemical Communications · doi:10.1039/c7cc02059g · Cited by 19
Jan, M., Upadhyay, C., Alcamí, J., Hioe, C. E., & Arora, S. K. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194498 · Cited by 19
Active targeting of nanoparticles: An innovative technology for drug delivery in cancer therapeutics
Jani, R., & Krupa, G. (2019) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v9i1-s.2356 · Cited by 21
Metadata
- Authors
- Pejchal, R., Doores, K. J., Walker, L. M., Khayat, R., Huang, P.-S., Wang, S.-K., Stanfield, R. L., Julien, J.-P., Ramos, A., Crispin, M., Depetris, R., Katpally, U., Marozsan, A., Cupo, A., Maloveste, S., Liu, Y., McBride, R., Ito, Y., Sanders, R. W., Ogohara, C., Paulson, J. C., Feizi, T., Scanlan, C. N., Wong, C.-H., Moore, J. P., Olson, W. C., Ward, A. B., Poignard, P., Schief, W. R., Burton, D. R., & Wilson, I. A.
- Affiliations
- Scripps Research Institute (US)
- University of Washington (US)
- University of Oxford (GB)
- Cornell University (US)
- Progenics Pharmaceuticals (United States) (US)
- National Institutes of Health (US)
- Imperial College London (GB)
- Japan Science and Technology Agency (JP)
- Corresponding author
- Pejchal, Robert
- Doores, Katie J.
- Walker, Laura M.
- Khayat, Reza
- Huang, Po-Ssu
- Burton, Dennis R.
- Wilson, Ian A.
- ORCID
- Doores, Katie J.
- Walker, Laura M.
- Khayat, Reza
- Huang, Po-Ssu
- Wang, Sheng-Kai
- Stanfield, Robyn L.
- Julien, Jean-Philippe
- Crispin, Max
- Depetris, Rafael
- Cupo, Albert
- Liu, Yan
- McBride, Ryan
- Ito, Yukishige
- Sanders, Rogier W.
- Paulson, James C.
- Feizi, Ten
- Wong, Chi-Huey
- Moore, John P.
- Olson, William C.
- Ward, Andrew B.
- Poignard, Pascal
- Schief, William R.
- Burton, Dennis R.
- Wilson, Ian A.
- Venue
- Science
- Published
- 2011-11-25
- Volume
- 334
- Issue
- 6059
- Pages
- 1097-1103
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3280215
- OpenAlex
- W2128579789
- Cited by
- 694
- References
- 75
- Citations by year
- 2026: 23 · 2025: 12 · 2024: 18 · 2023: 19 · 2022: 25 · 2021: 35 · 2020: 34 · 2019: 37 · 2018: 54 · 2017: 54 · 2016: 62 · 2015: 70 · 2014: 69 · 2013: 105 · 2012: 72
- FWCI
- 31.78
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- Canadian Institutes of Health Research (HFE-224662)
- Engineering and Physical Sciences Research Council (EP/G037604/1, GR/S79268/02)
- National Cancer Institute (Y1-CO-1020, U01CA128416)
- National Institute of General Medical Sciences (Y1-GM-1104)
- National Institute of Allergy and Infectious Diseases (AI-33292, F32AI074372, AI74372, R37AI033292, R56AI084817, P01AI082362, AI082362, R01AI033292, R01AI084817, AI84817)
- National Center for Research Resources (P41RR001209, RR017573, P41RR017573)
- Topics
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Keywords
- HIV-1, broadly neutralizing antibodies, gp120, glycan shield, V3 loop, antibody penetration
- MeSH terms
- Antibody Specificity, Epitopes, Binding Sites, Antibody, Carbohydrate Conformation, Cell Line, Disaccharides, Glycosylation, Humans, Hydrogen Bonding, Immunoglobulin Fab Fragments, Mannose, Mannosides, Models, Molecular, Mutation, Oligosaccharides, Polysaccharides, Protein Conformation, HIV Antibodies, HIV-1, HIV Envelope Protein gp120, Protein Structure, Tertiary, Crystallography, X-Ray, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.